


4-23-01 0300 042011 \$5



Practitioner's Docket No. MWH-0030US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Anastasio, Alison E.; Chew, Anne; Denton, R. Rex; Nandabalan, Krishnan; Parks, Katie E.; and Stephens, J. Claiborne

Application No.: 09/945,505 Group No.: to be assigned
Filed: August 31, 2001 Examiner: to be assigned

For: HAPLOTYPES OF THE TNFRSF1A GENE

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))
and
COMBINED DECLARATION AND POWER OF ATTORNEY
IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10*
(Express Mail label number is *mandatory*.)
(Express Mail certification is *optional*.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on Nov. 16, 2001 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL594594383US addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Cathy Wilcox
(type or print name of person mailing paper)

Signature of person mailing

Date: 16-November-2001

Sandra L. Shaner

Sandra L. Shaner
Registration No. 47,934
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
US
203-786-3468
Customer No. 25106

Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/945,505
Filing Date	08/31/2001
First Named Inventor	Alison E. Anastasio
Group Art Unit	
Examiner Name	
Attorney Docket Number	MWH-0030US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	AKSENTJEVICH I, ""The Tumor-Necrosis-Factor Receptor-Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers," Am. J. Hum. Genet, Vol. 69 (No. 1), p. 301-314, (July 6, 2001).	
	BB	BRUCE AJ, "Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors," Nature Medicine, Vol. 2 (No. 7), p. 788-794, (July 5, 1996).	
	BC	HOHMANN H, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)," J. Biol. Chem., Vol. 264 (No. 25), p. 14927-34, (September 5, 1989).	
	BD	LUCKENBACH C et al., "Restriction fragment length polymorphism: Molecular weight analysis and calculation with a scanner-based computer system," Electrophoresis, Vol. 15, NO. 2, p. 149-152 (February 1994).	
	BE	MCDERMOTT MF, "Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes," Cell, Vol. 97 (No. 1), p. 133-144, (April 2, 1999).	
	BF	ROTHER J, "Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes," Nature, Vol. 364 (No. 1), p. 798-802, (August 26, 1993).	
	BG	SCHIEVELLA AR, "MADD, a Novel Death Domain Protein That Interacts with the Type 1 Tumor Necrosis Factor Receptor and Activates Mitogen-activated Protein Kinase," J. Biol. Chem., Vol. 272 (No. 18), p. 12069-75, (May 22, 1997).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.